LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta‑analysis and bioinformatics analysis

Table 2 Meta-analysis results for the association between HCP5 expression and clinicopathological characteristics

Characteristics	Cancer type	OR (95% CI)	P value	I²%	Model
Age (old vs young)	CRC	0.86 (0.42, 1.79)	0.69
	OSCC	0.66 (0.26, 1.70)	0.39
	ccRCC	1.13 (0.43, 2.99)	0.80
	GC	1.28 (0.58, 2.85)	0.54
	Total	0.96 (0.63, 1.46)	0.85	0	Fixed
Gender (male vs female)	CRC	0.56 (0.27, 1.16)	0.12
	OSCC	1.22 (0.47, 3.18)	0.69
	ccRCC	0.58 (0.20, 1.63)	0.30
	GC	0.66 (0.29, 1.47)	0.31
	Total	0.69 (0.45, 1.06)	0.09	0	Fixed
Tumor size (large vs small)	CRC	0.52 (0.25, 1.09)	0.08
	ccRCC	2.10 (0.78, 5.63)	0.14
	GC	1.67 (0.68, 4.11)	0.26
	Total	1.17 (0.48, 2.88)	0.73	69	Random
Differentiation (poor vs well)	CRC	0.37 (0.17, 0.79)	0.01*
	GC	0.40 (0.18, 0.90)	0.03*
	Total	0.38 (0.22, 0.67)	0.0007*	0	Fixed
Lymph node metastasis (yes vs no)	CRC	2.48 (1.18, 5.21)	0.02*
	OSCC	0.33 (0.12, 0.88)	0.03*
	ccRCC	0.16 (0.05, 0.50)	0.002*
	GC	0.44 (0.19, 0.98)	0.04*
	Total	0.51 (0.16, 1.69)	0.27	86	Random
TNM stage (III–IV vs I–II)	CRC	1.37 (0.65, 2.91)	0.41
	OSCC	0.22 (0.08, 0.61)	0.004*
	GC	1.09 (0.49, 2.40)	0.84
	Total	0.73 (0.26, 2.01)	0.54	77	Random

OR odds ratio, CI confidence interval, CRC colorectal cancer, OSCC Oral squamous cell carcinoma, ccRCC clear cell renal cell carcinoma, GC gastric cancer
*P < 0.05

ISSN: 1475-2867